Information about Bard IVC Filter Lawsuits from Lawyers Handling IVC Filter Lawsuits

No-Cost, No-Obligation Bard IVC Filter Lawsuit Review

IVC Filter Lawsuits

Stanford's Dr. Kuo Has Helped Pioneer Advanced IVC Filter Laser Retrieval

Bard IVC Filter Lawsuits

The doctor has seen numerous IVC filter failure first hand that the patient had no idea was possible

Friday, January 28, 2022 - Thousands of IVC patients have been ignored by their doctors and have had their IVC blood clot trapping filters remain in place much longer than is safe. The FDA stresses that an IVC filter is a temporary solution and that a patient should be advised that the filter should be removed soon after it is implanted. The patient should also know that there is a long list of complications that have occurred when the device was left in. Patients that have suffered from a malfunctioning IVC filter should speak with an Bard IVC filter lawyer to see if they have a case to hold the manufacturer responsible for their negligence.

There are many reasons why IVC filters have failed and put the patient at risk of sudden death. IVC patients were told that implanting an IVC filter was a matter of life or death and did not bother to explain further. The odds of dying from a blood clot that traveled to the heart, lungs, or brain was better than 50-50, and for some, it was a certainty. What was omitted in the surgeon's sales presentation to the patient was the list of possible complications that were being reported to the Food and Drug Administration via their adverse events reporting database called the MAUDE system. The MAUDE reporting system is a part of the FDAs controversial 501 k fast track system that enable companies to rush life-saving medical devices like the IVC filter to market without the decade-long delay of pre-market human testing. The task of the FDA is to review their database frequently for reports made by surgeons, nurses, hospitals, patients, and others that demonstrated the medical device's shortcomings. According to DrugWatch.com, the FDA issued a Safety Alert after receiving an abnormally high number of adverse event database entries for the Bard IVC filter and other similar devices. "Possible complications of an IVC filter placement include, access site bleeding, misplacement, migration to the heart or lung, failure to open, filter fracture, infection, vein perforation, blockage of blood flow causing clots." Dr. William Kuo, an interventional radiologist and Professor of Interventional Radiology at Stanford University School of Medicine, told Drugwatch that he has seen it all when it comes to Bard IVC filter complications that patients had no previous idea possible, "Filter components can penetrate through the vein and cause pain, while some pieces can break, migrate and cause other problems. An old filter can also cause scarring in the vein leading to vessel occlusion, debilitating leg pain with swelling and greater risk for blood clots." Dr. Kuo stresses that an IVC filter can fail at any time. The longer that it is left in place, the greater the odds of that happening. FDA safety alerts inform doctors of their responsibility to follow up with IVC filters and get them removed, hopefully within 60-days, after the risks of blood clots had subsided.

More Recent IVC Filter Lawsuit News:

No-Cost, No-Obligation Bard IVC Filter Lawsuit Case Review for Persons or Families of Persons Who Suffered from Organ Damage, Severe Bleeding, Stroke, or Death

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others, and other law firms throughout the nation often seek its experience and expertise on complex litigation.